{"keywords": [{"value": "Valeant Pharmaceuticals International Inc", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Pershing Square Capital Management", "rank": "2", "is_major": "Y", "name": "organizations"}, {"value": "Ackman, William A", "rank": "3", "is_major": "Y", "name": "persons"}, {"value": "Drugs (Pharmaceuticals)", "rank": "4", "is_major": "N", "name": "subject"}, {"value": "Paulson & Co", "rank": "5", "is_major": "N", "name": "organizations"}, {"value": "Suits and Litigation (Civil)", "rank": "6", "is_major": "N", "name": "subject"}, {"value": "Pearson, John Michael (1959- )", "rank": "7", "is_major": "N", "name": "persons"}, {"value": "Hedge Funds", "rank": "8", "is_major": "N", "name": "subject"}, {"value": "Citron Research", "rank": "9", "is_major": "N", "name": "organizations"}], "headline": {"print_headline": "Valeant\u2019s Shares Fall on Report\u2019s Fraud Claim", "main": "Valeant\u2019s Shares Fall on Report\u2019s Fraud Claim"}, "byline": {"contributor": "Andrew Pollack contributed reporting.", "original": "By MATTHEW GOLDSTEIN, ALEXANDRA STEVENSON and PETER EAVIS", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "GOLDSTEIN", "firstname": "Matthew"}, {"rank": 2, "role": "reported", "organization": "", "lastname": "STEVENSON", "firstname": "Alexandra"}, {"rank": 3, "role": "reported", "organization": "", "lastname": "EAVIS", "firstname": "Peter"}]}, "web_url": "http://www.nytimes.com/2015/10/22/business/dealbook/valeants-shares-fall-on-reports-fraud-claim.html", "source": "The New York Times", "subsection_name": "DealBook", "slideshow_credits": null, "type_of_material": "News", "_id": "562840d138f0d80f1ae08bf1", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/22/business/22Valeant/22Valeant-thumbWide-v2.jpg"}, "type": "image", "width": 190, "url": "images/2015/10/22/business/22Valeant/22Valeant-thumbWide-v2.jpg"}, {"height": 399, "subtype": "xlarge", "legacy": {"xlargeheight": "399", "xlargewidth": "600", "xlarge": "images/2015/10/22/business/22Valeant/22Valeant-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/10/22/business/22Valeant/22Valeant-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2015/10/22/business/22Valeant/22Valeant-thumbStandard-v2.jpg"}, "type": "image", "width": 75, "url": "images/2015/10/22/business/22Valeant/22Valeant-thumbStandard-v2.jpg"}], "pub_date": "2015-10-22T00:00:00Z", "print_page": "1", "section_name": "Business Day", "word_count": "1305", "blog": [], "news_desk": "Business", "snippet": "A research firm\u2019s report that all but called Valeant the pharmaceutical equivalent of Enron hit the stock market like a bomb Wednesday morning.", "document_type": "article", "abstract": "Shares of Valeant Pharmaceutical fall after report by Citron Research accuses it of accounting fraud; report contends Valeant dealt in 'phantom sales;' Pershing Square Capital head William A Ackman increases share in company.", "lead_paragraph": "A research firm\u2019s report that all but called Valeant the pharmaceutical equivalent of Enron hit the stock market like a bomb Wednesday morning."}